斯帕拉明钛/先灵公司
Spheramine Titan/Schering.
作者信息
Grosset Donald, Grosset Katherine
机构信息
Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK.
出版信息
Curr Opin Investig Drugs. 2005 Jul;6(7):722-8.
PMID:16044669
Abstract
Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006.
摘要
斯佩拉明由包被有能产生多巴胺的人类视网膜色素上皮细胞的微载体组成，目前由泰坦公司和先灵公司进行研发，用于潜在治疗晚期帕金森病。2005年3月二期试验正在进行，当时预计在2006年下半年完成。
Zotero 插件